Biotech closes on $9M for stem cell, cord blood research

09/14/2007 | American City Business Journals

Aldagen has raised $9 million in funding to use for its research with stem cells derived from bone marrow, blood and umbilical cords. The biotech company currently has three drugs trials under way for improving safety in cord blood transfusions and treating advanced heart failure and blocked extremities.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ